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Abstract
Background: The emergence of drug resistance is one of the most important threats to tuberculosis control programs.
This study was aimed to analyze the frequency of gene mutations associated with resistance to isoniazid (INH),
rifampicin (RMP) and ethambutol (EMB) among Mycobacterium tuberculosis isolates from Northwest Ethiopia, and to
assess the performance of the GenoType® MTBDRplus and GenoType® MTBDRsl assays as compared to the BacT/ALERT
3D system.
Methods: Two hundred sixty Mycobacterium tuberculosis isolates from smear positive tuberculosis patients
diagnosed between March 2009 and July 2009 were included in this study. Drug susceptibility tests were
performed in the Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University Hospital of
Leipzig, Germany.
Results: Of 260 isolates, mutations conferring resistance to INH, RMP, or EMB were detected in 35, 15, and 8
isolates, respectively, while multidrug resistance (MDR) was present in 13 of the isolates. Of 35 INH resistant strains,
33 had mutations in the katG gene at Ser315Thr 1 and two strains had mutation in the inhA gene at C15T. Among
15 RMP resistant isolates, 11 had rpoB gene mutation at Ser531Leu, one at His526Asp, and three strains had
mutations only at the wild type probes. Of 8 EMB resistant strains, two had mutations in the embB gene at
Met306Ile, one at Met306Val, and five strains had mutations only at the wild type probes. The GenoType®
MTBDRplus assay had a sensitivity of 92% and specificity of 99% for INH resistance, and 100% sensitivity and
specificity to detect RMP resistance and MDR. The GenoType® MTBDRsl assay had a sensitivity of 42% and
specificity of 100% for EMB resistance.
Conclusion: The dominance of single gene mutations associated with the resistance to INH and RMP was
observed in the codon 315 of the katG gene and codon 531 of the rpoB gene, respectively. The GenoType®
MTBDRplus assay is a sensitive and specific tool for diagnosis of resistance to INH, RMP and MDR. However, the
GenoType® MTBDRsl assay shows limitations in detecting resistance to EMB.
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Background
According to the World Health Organization (WHO)
report, the proportion of multidrug resistant tuberculo-
sis (MDR-TB), resistant to at least isoniazid and rifampi-
cin among new and previously treated TB cases globally
ranges from 0% to 28.3% and from 0% to 61.6%,
respectively [1]. In Ethiopia, the countrywide anti-TB
drug resistance survey conducted in 2005 showed that
the prevalence of MDR-TB was 1.6% and 11.8% among
new and previously treated TB cases, respectively [2].
Moreover, 5825 MDR-TB cases were estimated to have
occurred in 2006 in Ethiopia [3]. MDR-TB treatment
involves prolonged use of second-line anti-TB drugs
that are less effective, less tolerated, more toxic, and
more expensive than first-line anti-TB drugs [4]. In
most high-burden TB countries, MDR-TB is only
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diagnosed after prolonged treatment with first-line TB
drugs and clinical recognition that treatment has failed.
Treatment of drug-resistant TB with standard first-line
drugs, instead of a regimen designed according to the
resistance pattern has several potential adverse conse-
quences: patients remain on inadequate treatment
longer, increasing the risk of treatment failure or death;
selection of drug resistant strains and patients remain
infectious, promoting transmission to close contacts [5].
In Ethiopia, the treatment regimens for category I and
category II (retreatment regimen) tuberculosis cases are
2 (RMP-INH-EMB-PZA)/4(RMP-INH) and 2 STM
(RMP-INH-EMB-PZA)/1(RMP-INH-EMB-PZA)/5(EMB3
(RMP-INH)3), respectively [6]. The standard treatment
regimen for MDR-TB is 6(EMB-PZA-KM (AMK)-LFX-
ETO-CS)/12(EMB-PZA-LFX-ETO-CS). For proper
treatment and control of tuberculosis, WHO is recom-
mending countries to expand their capacity for culture
based drug-susceptibility testing (DST) and consider
new, molecular-based assays for diagnosing drug resis-
tance [7,8]. Since M. tuberculosis usually grows slowly,
the identification and drug-resistance testing usually
require several weeks. The gold-standard of TB diagno-
sis by culture takes weeks to become positive, and even
with the up-to date automated fluid culture methods it
takes an average of 14 days. Another 14 days for addi-
tional testing are required to get the information on
drug susceptibility [9-11]. Molecular methods of drug
resistance testing, based on the identification of muta-
tions in genes associated with drug resistance, like Gen-
eXpert MTB/RIF assay, offer an effective tool for
determining drug resistance because of their high sensi-
tivity, specificity and speed [12].
Molecular methods that have been developed to detect
drug resistance include the GenoType® MTBDRplus for
detection of INH and RMP resistance and the Geno-
Type® MTBDRsl for detection of resistance against
EMB, floroquinolones, and aminoglycosides/cyclic pep-
tides (Hain Lifescience, Nehren, Germany). These assays
are DNA strip assays that use PCR and hybridization.
Mutations in katG gene and inhA gene were related to
the high-level and low-level INH resistance, respectively
[13]. Nearly all RMP resistant strains contain mutation
of the rpoB gene, coding RNA polymerase subunit ß
and mutation in the embB gene was associated with
EMB resistance [14,15].
In Ethiopia, culture and drug susceptibility testing
(DST) for M. tuberculosis are not performed routinely
in clinical microbiology laboratories. Laboratory diagno-
sis of TB remains in a stage of acid-fast staining. Cur-
rently, five regional laboratories are being rebuilt and
equipped to perform culture and drug susceptibility test-
ing using methods including GenoType® MTBDRplus
assay. The GenoType® MTBDRplus and GenoType®
MTBDRsl assays have been studied in several labora-
tories of other countries, however, there is a wide varia-
tion in circulating M. tuberculosis strains worldwide
[16,17], and false negative results may occur due to
unique genetic mutations [18-24], affecting the perfor-
mance of molecular assays for drug susceptibility testing.
Therefore, analysis of gene mutations associated with
resistance to anti-tuberculosis drugs and assessment of
the performance of molecular methods for drug resis-
tance testing in different settings are needed to ensure
acceptable performance of the assays. So far, there was
no report on the frequency of gene mutations associated
with resistance to INH, RMP and EMB and the applic-
ability of these molecular assays for M. tuberculosis iso-
lates from Ethiopia. In this study, we analyzed the
frequency of gene mutations associated with resistance
to INH, RMP and EMB among M. tuberculosis isolates
from Northwest Ethiopia, and assessed the performance
of the GenoType® MTBDRplus for detection of resis-
tance to INH, RMP and MDR and GenoType®
MTBDRsl assay for detection of EMB resistance com-
pared to the automated, culture-based, BacT/ALERT 3D
system drug susceptibility testing.
Methods
Study design, area and study period
Two hundred sixty M. tuberculosis isolates from smear
positive tuberculosis patients diagnosed between March
2009 and July 2009 at Gondar Hospital, Gondar Health
Center, Metemma Hospital, Bahir Dar Hospital and
Debre Markos Hospital in Northwest Ethiopia were
included in this study. Diagnosis of smear-positive
tuberculosis was based on the national guideline for
microscopic examination of tuberculosis (6): direct
smears were prepared from three sputum specimens
and stained by Ziehl-Neelsen staining technique for
microscopic examination. Drug susceptibility tests using
GenoType® MTBDRplus, GenoType® MTBDRsl and
BacT/ALERT 3D system were performed at the myco-
bacteriology laboratory in the Institute of Medical
Microbiology and Epidemiology of Infectious Diseases,
University Hospital of Leipzig, Germany. Informed con-
sent was obtained from the study subjects. Institutional
ethical clearance was obtained from the research and
publication committee of Gondar University, Ethiopia.
Details of sputum storage, transportation, isolation and
identification of the isolates have described previously
[25].
GenoType® MTBDRplus and GenoType® MTBDRsl drug
susceptibility testing
GenoType® MTBDRplus assay for detection of INH and
RMP resistance, and GenoType® MTBDRsl assay for
detection of ethambutol resistance were performed
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according to the manufacturer’s instructions (Hain Life-
science GmbH, Nehren, Germany). Briefly, DNA was
extracted from cultures by heating the bacteria in a
heating block for 20 minutes at 95°C followed by sonica-
tion in ultrasonic water bath for 15 minutes. Amplifica-
tion was performed using 2.5 μl (1 unit) Taq DNA
polymerase (ROCHE, Mannheim, Germany). For the
amplification profile the instructions of the manufac-
turer were followed. Hybridization of the single-
stranded, biotin-labeled amplicons to membrane-bound
probes on the strip followed by addition of conjugate,
and substrate to detect visible band patterns on the strip
was performed manually using a shaking water bath,
Memmert-SV1422 (Memmert GmbH & CO.KG, Schwa-
bach, Germany) at 45°C. Then strips were allowed to
dry and interpreted according to the manufacturer’s
recommendation.
To detect high level INH resistance, the GenoType®
MTBDRplus has incorporated one wild type (WT-315)
and two mutation-type probes specific for mutation
Ser315Thr1 and Ser315Thr2 of the katG gene. For
detection of low-level INH resistance this assay has two
wild-type probes (WT-15/-16 and WT-8) and four
mutation-type probes, covering mutations of C15T,
A16G, T8C and T8A in the inhA gene. To detect rifam-
picin resistance, the Genotype MTBDRplus has incorpo-
rated eight wild-type probes for the rpoB gene, covering
codons in the rpoB gene from 505 to 533, and four
other probes specific for mutations Asp516Val, His526-
Tyr, His526Asp and Ser531Leu. For detection of etham-
butol resistance, the GenoType® MTBDRsl employs one
wild-type probe (WT-306) and two mutation probes
specific for mutations Met306Ile and Met306Val in the
embB gene.
BacT/ALERT 3D system drug susceptibility testing
Drug susceptibility testing for isoniazid, rifampicin and
ethambutol was performed by BacT/ALERT 3D system
(BioMerieux, S.A, France) according to the methods
published previously [26,27]. The final drug concentra-
tion in the test bottles was 1 μg/ml for INH and RMP,
and 2 μg/ml for EMB. Two control bottles, one with 1%
control (0.5 ml of the 1:100 diluted test organisms sus-
pension) and one original control bottle without drug
were used for interpretation of the test results. M. tuber-
culosis isolate was determined to be resistant to an anti-
biotic when the drug-containing bottle had a time to
detection (TTD) that was less than or equal to the TTD
of the 1% control.
Statistical analysis
All laboratory data were entered, cleared and analyzed
using SPSS version 13 statistical package software (SPSS
Inc., Chicago, IL). The standard chi-square tests (c2)
were used to assess statistical relationships between pre-
disposing factors and drug-resistant TB. Sensitivity, spe-
cificity, positive predictive value and negative predictive
value of the molecular methods were analyzed using
crosstabulation after arranging the results of the mole-
cular methods in the rows and gold standard, BacT/
ALERT 3D system in columns. P values of less than
0.05 were considered statistically significant.
Results
Of the 260 patients included in this study, the majority
of patients, 59% were males. The median age of the
study subjects was 28.0 years (range, 7-75 years). History
of previous treatment for tuberculosis was significantly
associated with gene mutations conferring resistance to
INH (P = 0.001), RMP (P = 0.002) and MDR (P =
0.044). HIV co-infection, gender and age of the study
subjects had no significant association with gene muta-
tions conferring resistance to INH, RMP and EMB. A
summary of patient demographic characteristics and
associated drug susceptibility pattern according to the
molecular methods is shown in Table 1.
Mutations associated with INH, RMP and EMB resistance
Mutations conferring resistance to isoniazid, rifampicin
and ethambutol were detected in 14%, 6% and 3% of the
isolates, respectively. Five percent of the isolates showed
mutation in both rpoB gene and katG gene or inhA pro-
moter region indicating that they were multidrug resis-
tant. There was no isolate that showed mutations at
both katG and inhA genes. Mutations associated with
isoniazid resistance were more often encountered as
compared to those seen in rifampicin and ethambutol.
Of 35 INH resistant strains, 94% had mutation in the
katG (codon 315) gene with amino acid change of
Ser315Thr1, indicating high level resistance, while 6% of
the strains had mutation in the inhA gene, C15T, indi-
cating low level resistance. All katG gene mutations
detected at wild type probes were also present at mutant
probes, as was the case with the inhA gene mutations
(Table 2). Additionally, three strains showing resistance
to isoniazid and two strains sensitive to isoniazid by the
BacT/ALERT 3D system did not display concordant
results by GenoType® MTBDRplus even on repeat
assays (Table 3).
The rifampicin resistant isolates displayed different
mutations: 73% of the isolates had mutation at position
Ser531Leu, one isolate had mutation at His526Asp,
while in three of the isolates mutation was detected only
at the wild type probes. Of the isolates with mutation
that detected only at wild type probes, one isolate had
mutation at rpoB WT2 and WT3, one isolate at rpoB
WT4 and one isolate at rpoB WT6. According to the kit
manufacturer’s recommendation, the three isolates with
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mutation that detected only at wild type probes were
considered resistant (Table 2).
Mutations associated with ethambutol resistance were
less frequent compared to those seen in isoniazid and
rifampicin resistance. Of the 8 EMB resistant strains
according to the molecular method, two strains had muta-
tions in the embB (codon 306) gene with amino acid
change of Met306Ile and one strain had mutation in the
embB gene with amino acid change of Met306Val,
whereas five strains had mutation that detected only at the
wild type probes (embB WT) but not at the mutant probes
(Table 2). Moreover, 58% of the isolates showing resis-
tance to ethambutol by the BacT/ALERT 3D system did
not display a concordant result by GenoType® MTBDRsl
assay even on repeat assays (Table 3). All isolates included
in this study had no mutations conferring resistance to
fluoroquinolones and aminoglycosides. This might be due
to low use/access to these drugs in Northwest Ethiopia.
Performance of GenoType® MTBDRplus and GenoType®
MTBDRsl assays
Compared with the automated, culture-based, BacT/
ALERT 3D system drug susceptibility testing, the Geno-
Type® MTBDRplus assay had a sensitivity of 92% and
specificity of 99% for detection of INH resistance, a sen-
sitivity of 100% and specificity of 100% for RMP resis-
tance, and a sensitivity of 100% and specificity of 100%
for multidrug resistance. The GenoType® MTBDRsl
assay had a sensitivity of 42% and specificity of 100% for
detection of EMB resistance (Table 3).
Table 1 Characteristics of study subjects and their association with resistance to isoniazid, rifampicin and ethambutol
based on GenoType® MTBDRplus and GenoType® MTBDRsl assays











Male 153 19 (12.4) 0.556 9 (5.9) 0.925 7 (4.6) 0.707 5 (3.3) 0.831
Female 107 16 (15.0) 6 (5.6) 6(5.6) 3 (2.8)
Age (years)
< 40 214 29 (13.6) 0.927 11 (5.1) 0.348 9 (4.2) 0.205 7 (3.3) 0.696
≥ 40 46 6 (13.0) 4 (8.7) 4 (8.7) 1 (2.2)
TB history
New 214 22 (10.3) 0.001 8 (3.7) 0.002 8(3.7) 0.044 6 (2.8) 0.582
Previously treated 46 13 (28.3) 7 (15.2) 5 (10.9) 2 (4.3)
HIV status
Negative 194 29 (14.9) 0.228 9 (4.6) 0.180 9 (4.6) 0.647 7 (3.6) 0.395
Positive 66 6 (9.1) 7 (10.6) 4 (6.1) 1 (1.5)
Total 260 35 (13.5) 15 (5.8) 13 (5.0) 8 (3.1)
N number, INH isoniazid, RMP rifampicin, MDR multidrug resistance, EMB ethambutol
Table 2 Frequency of gene mutations associated with resistance to isoniazid and rifampicin by GenoType®
MTBDRplus, and to ethambutol by GenoType® MTBDRsl assays
Anti TB-drugs Number of resistant isolates Patterns of gene mutations (wild-type/mutant) Amino acid
Changes
Frequency (n)
Isoniazid 35 katGWT/katGMUT1 Ser315Thr1 33
inhA WT1/inhA MUT1 C15T 2
Rifampicin 15 rpoB WT8/rpoB MUT3 Ser531Leu 11
rpoB WT7/rpoB MUT2B His526Asp 1
rpoB WT2 &3/NA Unknown 1
rpoB WT4/ND Unknown 1
rpoB WT6/NA Unknown 1
Ethambutol 8 embB WT/embB MUT1A Met306Ile 2
embB WT/embB MUT1B Met306Val 1
embB WT/ND Unknown 5
n number of isolates, WT wild-type, MUT mutant, ND no mutation detected at mutant probe, NA mutant probe is not available
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Discussion
Almost all TB laboratories in Ethiopia have only been
equipped with the acid-fast staining and lack resources
for culture, identification and drug susceptibility testing
of mycobacteria, which present a huge hindrance for
tuberculosis control in the country. Therefore, there is
an urgent need for laboratories to find a rapid and effi-
cient method for TB diagnosis as a complement to the
smear microscopy, and meanwhile to establish MDR-TB
diagnostic route for rapid detection of drug-resistant
TB. The GenoType® MTBDRplus and GenoType®
MTBDRsl assays are rapid and technically simple to per-
form and do not require sophisticated equipment when
compared with the conventional culture-based techni-
ques. These assays have been studied in other countries.
However, false negative results reported due to unique
genetic mutations associated with resistance to anti-
tuberculosis drugs in different countries [18-24]. There-
fore, in this study, we investigated the frequency of gene
mutations associated with resistance to INH, RMP and
EMB and evaluated the performance of these molecular
assays for detection of resistance to INH, RMP and
EMB on M. tuberculosis isolates from Northwest
Ethiopia.
In this study, the GenoType® MTBDRplus assay had a
sensitivity of 92% and specificity of 99% for INH resis-
tance, and 100% sensitivity and specificity for RMP
resistance and for multidrug resistance. Other reports
have shown that the performance of the GenoType®
MTBDRplus assay in sensitivity and specificity almost
comes up to that of conventional culture-based suscept-
ibility testing: Causse et al. [28] reported a sensitivity of
95% for INH and 100% for RMP, a Meta analysis report
by Bawanga et al. [29] showed that GenoType®
MTBDRplus assay has a sensitivity and specificity of
96% and 100% for INH and 99% and 99% for RMP,
respectively. In the present study, 8% of phenotypically
defined isoniazid-resistant strains had no mutations in
codon 315 of the katG gene and in the regulatory region
of the inhA gene, demonstrating that other mechanisms
or mutations in other codons of the katG gene may be
responsible for the development of INH resistance in M.
tuberculosis strains. Interestingly, all phenotypically
defined rifampicin-resistant strains and multidrug-resis-
tant strains had mutations conferring resistance to
rifampicin, and both isoniazid and rifampicin resistance
(MDR). Suggesting that the set of the DNA probes used
in the GenoType® MTBDRplus assay covers most of the
mutations prevalent in Northwest Ethiopia. However,
previously reported associations between the gene muta-
tions and Beijing strains [30,31] suggest that the assay
may be potentially useful in the area with a high preva-
lence of Beijing family (Eastern Europe, China and
South-East Asia).
Previous studies have shown that 40-95% of isoniazid
resistance are defined as the high-level drug-resistance
due to the katG gene mutations. Of which, 75-90% are
recognized as mutations in the 315th codon of the katG
gene, which mainly result in Ser315Thr1 and
Ser315Thr2 mutation [13,15,32]. In the present study,
94% of INH resistances, close to the high limit of
reported range, were attributed to katG mutations
which confer high level resistance to INH. Of which,
100% were identified as Ser315Thr1 mutation. Studies
have also shown that 8% to 43% of INH resistance are
defined as the low-level drug resistance mainly caused
by the mutations in the promoter region of inhA gene
[33]. In this study, we have observed that the low-level
drug-resistance proportion was 6%, close to the low
limit of the reported range.
In the previous studies [14,15,34], about 95% of resis-
tance to RMP are associated with the rpoB gene muta-
tions which are found to cluster mainly in the region of
codon 507-533. In this study, the distribution of gene
Table 3 Performance of GenoType® MTBDRplus assay for detection of resistance to INH, RMP and MDR and
GenoType® MTBDRsl assay for detection of EMB resistance in comparison to BacT/ALERT 3D system
Molecular methods
DST results









INH Susceptible 222 3 91.7 99.1 94.3 98.7
Resistant 2 33




Susceptible 247 0 100 100 100 100
Resistant 0 13
EMB Susceptible 241 11 42 100 100 95.6
Resistant 0 8
DST drug susceptibility testing, INH isoniazid, RMP rifampicin, MDR multidrug resistance, EMB ethambutol, PPV positive predictive value, NPV negative predictive
value
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mutation among RMP resistant isolates was 73% at posi-
tion Ser531Leu and 7% at His526Asp. In 20% of the
resistant isolates, mutation was detected only at the wild
type probes, which is different from the previously
reported gene mutation distribution in China, 37% at
Ser531Leu, 3% at His526Asp and in 60% of the isolates,
mutation was detected only at the wild type probes [35],
reflecting the difference in the distribution of gene
mutations associated with RMP resistance in different
geographical locations. The high frequency (20%) of
RMP resistant isolates with no mutation at the mutant
probes, probably indicating the presence of less common
mutations at rpoB gene that can not be detected by the
current version of the GenoType® MTBDRplus assay.
In this study, the distribution of gene mutation among
8 isolates showing resistance to EMB by GenoType®
MTBDRsl assay was 25% at Met306Ile, 13% at Met306-
Val and 63% of the strains had mutation only at the
wild type probes. Furthermore, 58% of the isolates
showing resistance to ethambutol by the BacT/ALERT
3D system did not display a similar result by this mole-
cular assay even on repeat assays. Consequently, in the
present study, GenoType® MTBDRsl assay had sensitiv-
ity of 42% and specificity of 100% for ethambutol resis-
tance. Similarly, other previous studies have shown that
this assay has low sensitivity, only about 50% for detec-
tion of EMB resistance [36-38]. The present study
together with previous reports, highlight the fact that
the molecular basis of EMB resistance in M. tuberculosis
is still insufficiently understood to allow detection of
EMB resistance by molecular methods.
Conclusions
In our study, the dominance of single gene mutations
associated with the resistance to isoniazid and rifampi-
cin in the codon 315 of the katG gene and codon 531
of the rpoB gene was observed. The GenoType®
MTBDRplus assay is a sensitive and specific tool for
diagnosis of resistance to INH, RMP and MDR. The
short turnaround times and the potential for rapid
screening of large numbers of isolates make it suitable
as a first-line screening assay for TB drug resistance. Its
application and popularization will help better solve the
long-standing problem of laboratory diagnosis of drug
resistance in Ethiopia. In the majority of phenotypically
ethambutol resistant isolates, gene mutation associated
with the resistance to ethambutol was not detected by
this assay. This indicates that the present version of the
GenoType® MTBDRsl assay shows limitations in detect-
ing resistance to ethambutol. Further studies are
required to understand the mechanism of resistance to
ethambutol and to evaluate GenoType® MTBDRplus
assay for the diagnosis of INH and RMP resistance from
direct sputum specimens of tuberculosis patients in
Ethiopia.
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